methyl 2-(5-(cyclopropylsulfonyl)-1H-indazol-1-yl)-3-(tetrahydro-2H-pyran-4-yl)propanoate | 1196875-78-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-(5-(cyclopropylsulfonyl)-1H-indazol-1-yl)-3-(tetrahydro-2H-pyran-4-yl)propanoate
• 英文别名: Methyl 2-(5-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanoate
• CAS: 1196875-78-1
• 化学式: C₁₉H₂₄N₂O₅S
• 分子量: 392.476
• InChiKey: UZCGATIRUAFFAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  95.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 2-(5-(cyclopropylsulfonyl)-1H-indazol-1-yl)-3-(tetrahydro-2H-pyran-4-yl)propanoate 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-N-(5-chlorothiazol-2-yl)-2-(5-(cyclopropylsulfonyl)-1H-indazol-1-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide
  参考文献：
  名称：

  Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators

  摘要：

  Guided by co-crystal structural information obtained from a different series we were exploring, a scaffold morphing and SBDD approach led to the discovery of the 1,4-disubstituted indazole series as a novel class of GKAs that potently activate GK in enzyme and cell assays. anti-diabetic OGTT efficacy was demonstrated with 29 in a rodent models of type 2 diabetes. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.04.041
• 作为产物：
  描述：

  5-溴吲唑 在 copper(l) iodide 、 二甲基十二/十四烷基叔胺 、 sodium hydride 、 potassium carbonate 作用下， 生成 methyl 2-(5-(cyclopropylsulfonyl)-1H-indazol-1-yl)-3-(tetrahydro-2H-pyran-4-yl)propanoate
  参考文献：
  名称：

  Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators

  摘要：

  Guided by co-crystal structural information obtained from a different series we were exploring, a scaffold morphing and SBDD approach led to the discovery of the 1,4-disubstituted indazole series as a novel class of GKAs that potently activate GK in enzyme and cell assays. anti-diabetic OGTT efficacy was demonstrated with 29 in a rodent models of type 2 diabetes. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.04.041

文献信息

• Glucokinase Activators
  申请人：Cheruvallath Zacharia

  公开号：US20090286800A1

  公开（公告）日：2009-11-19

  Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供了用于与葡萄糖激酶一起使用的化合物，其化学式如下：其中变量如本文所定义。还提供了包含这些化合物的药物组合物、试剂盒和制造品；用于制备这些化合物的有用中间体和方法；以及使用这些化合物的方法。
• GLUCOKINASE ACTIVATORS
  申请人：Takeda San Diego, Inc.

  公开号：EP2294053A2

  公开（公告）日：2011-03-16
• US8563730B2
  申请人：——

  公开号：US8563730B2

  公开（公告）日：2013-10-22
• US9139598B2
  申请人：——

  公开号：US9139598B2

  公开（公告）日：2015-09-22
• [EN] GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE LA GLUCOKINASE
  申请人：TAKEDA SAN DIEGO INC

  公开号：WO2009140624A2

  公开（公告）日：2009-11-19

  Compounds are provided for use with glucokinase that comprise the formula: ##STR## wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.